Exact Mass: 509.1237

Exact Mass Matches: 509.1237

Found 129 metabolites which its exact mass value is equals to given mass value 509.1237, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

N6,N6,O-Tridemethylpuromycin-5-phosphate

C19H24N7O8P (509.1424)

NK 250

Bis(pyridin-4-ylmethyl) 2,6-dimethyl-4-(6-methyl-2,3-dihydro-1,4-dithiin-5-yl)-1,4-dihydropyridine-3,5-dicarboxylate

C26H27N3O4S2 (509.1443)

Fluphenazine hydrochloride

Fluphenazine (dihydrochloride)

C22H28Cl2F3N3OS (509.1282)

D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent

4-cis-Hydroxycyclohexyl glyburide

5-chloro-2-methoxy-N-(2-{4-[({[(1s,4s)-4-hydroxycyclohexyl]-C-hydroxycarbonimidoyl}amino)sulfonyl]phenyl}ethyl)benzene-1-carboximidic acid

C23H28ClN3O6S (509.1387)

4-cis-Hydroxycyclohexyl glyburide is a metabolite of glyburide. Glibenclamide, also known as glyburide (USAN), is an antidiabetic drug in a class of medications known as sulfonylureas, closely related to sulfa drugs. It was developed in 1966 in a cooperative study between Boehringer Mannheim (now part of Roche) and Hoechst (now part of Sanofi-Aventis). (Wikipedia)

2-trans-Hydroxycyclohexyl glyburide

5-chloro-N-(2-{4-[({[(1S,2S)-2-hydroxycyclohexyl]-C-hydroxycarbonimidoyl}amino)sulfonyl]phenyl}ethyl)-2-methoxybenzene-1-carboximidic acid

C23H28ClN3O6S (509.1387)

2-trans-Hydroxycyclohexyl glyburide is a metabolite of glyburide. Glibenclamide, also known as glyburide (USAN), is an antidiabetic drug in a class of medications known as sulfonylureas, closely related to sulfa drugs. It was developed in 1966 in a cooperative study between Boehringer Mannheim (now part of Roche) and Hoechst (now part of Sanofi-Aventis). (Wikipedia)

4-trans-Hydroxycyclohexyl glyburide

5-chloro-2-methoxy-N-(2-{4-[({[(1r,4r)-4-hydroxycyclohexyl]-C-hydroxycarbonimidoyl}amino)sulfonyl]phenyl}ethyl)benzene-1-carboximidic acid

C23H28ClN3O6S (509.1387)

4-trans-Hydroxycyclohexyl glyburide is a metabolite of glyburide. Glibenclamide, also known as glyburide (USAN), is an antidiabetic drug in a class of medications known as sulfonylureas, closely related to sulfa drugs. It was developed in 1966 in a cooperative study between Boehringer Mannheim (now part of Roche) and Hoechst (now part of Sanofi-Aventis). (Wikipedia)

3-trans-Hydroxycyclohexyl glyburide

5-chloro-N-(2-{4-[({[(1R,3R)-3-hydroxycyclohexyl]-C-hydroxycarbonimidoyl}amino)sulfonyl]phenyl}ethyl)-2-methoxybenzene-1-carboximidic acid

C23H28ClN3O6S (509.1387)

3-trans-Hydroxycyclohexyl glyburide is a metabolite of glyburide. Glibenclamide, also known as glyburide (USAN), is an antidiabetic drug in a class of medications known as sulfonylureas, closely related to sulfa drugs. It was developed in 1966 in a cooperative study between Boehringer Mannheim (now part of Roche) and Hoechst (now part of Sanofi-Aventis). (Wikipedia)

3-cis-Hydroxycyclohexyl glyburide

5-chloro-N-(2-{4-[({[(1R,3S)-3-hydroxycyclohexyl]-C-hydroxycarbonimidoyl}amino)sulfonyl]phenyl}ethyl)-2-methoxybenzene-1-carboximidic acid

C23H28ClN3O6S (509.1387)

3-cis-Hydroxycyclohexyl glyburide is a metabolite of glyburide. Glibenclamide, also known as glyburide (USAN), is an antidiabetic drug in a class of medications known as sulfonylureas, closely related to sulfa drugs. (Wikipedia)

3-Hydroxyglibenclamide

5-chloro-N-{2-[4-({[(3-hydroxycyclohexyl)carbamoyl]amino}sulfonyl)phenyl]ethyl}-2-methoxybenzamide

C23H28ClN3O6S (509.1387)

Flumethrin

cyano(4-fluoro-3-phenoxyphenyl)methyl 3-[2-chloro-2-(4-chlorophenyl)ethenyl]-2,2-dimethylcyclopropane-1-carboxylate

C28H22Cl2FNO3 (509.0961)

rac trans-4-Hydroxy Glyburide

5-Chloro-N-{2-[4-({[(4-hydroxycyclohexyl)-C-hydroxycarbonimidoyl]amino}sulphonyl)phenyl]ethyl}-2-methoxybenzene-1-carboximidic acid

C23H28ClN3O6S (509.1387)

Ripretinib

N-{4-bromo-5-[1-ethyl-7-(methylimino)-2-oxo-1,2,6,7-tetrahydro-1,6-naphthyridin-3-yl]-2-fluorophenyl}-n-phenylcarbamimidate

C24H21BrFN5O2 (509.0863)

8-(Methylsulfonyl)octyl glucosinolate

C16H31NO11S3 (509.1059)

4,5,6,7-Tetrahydroxydecyl glucosinolate

C16H31NO13S2 (509.1237)

((2R,3R,4S,5R)-5-(2-amino-6-oxo-1,6-dihydropurin-9-yl)-4-hydroxy-3-((2R,4S,5S)-3,4,5-trihydroxy-6-methyl-tetrahydro-2H-pyran-2-yloxy)-tetrahydrofuran-2-yl)methyl hydrogen sulfate

C16H23N5O12S (509.1064)

Evista

Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-, hydrochloride (1:1)

C28H28ClNO4S (509.1427)

Raloxifene hydrochloride is a hydrochloride salt resulting from the reaction of equimolar amounts of raloxifene and hydrogen chloride. It has a role as a bone density conservation agent, an estrogen antagonist and an estrogen receptor modulator. It contains a raloxifene(1+). Raloxifene Hydrochloride is the hydrochloride salt form of raloxifene, a selective benzothiophene estrogen receptor modulator (SERM) with lipid lowering effects and activity against osteoporosis. Raloxifene hydrochloride specifically binds to estrogen receptors in responsive tissue, including liver, bone, breast, and endometrium. The resulting ligand-receptor complex is translocated to the nucleus where, depending on the tissue type, it promotes or suppresses the transcription of estrogen-regulated genes, thereby exerting its agonistic or antagonistic effects. This agent functions as an estrogen agonist in lipid metabolism, thereby decreasing total and LDL cholesterol levels. In tissue like bone, it decreases bone resorption and bone turnover and increases bone mineral density. Raloxifene hydrochloride acts as an estrogen antagonist in uterine and breast tissue. This agent also exerts an anti-proliferative effect on estrogen-sensitive breast cancer. A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue. See also: Raloxifene (has active moiety). D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D020847 - Estrogen Receptor Modulators D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist D050071 - Bone Density Conservation Agents C1892 - Chemopreventive Agent Raloxifene hydrochloride (Keoxifene hydrochloride) is a second generation?selective and orally active estrogen receptor modulator. Raloxifene hydrochloride produces estrogen-agonistic effects on bone and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast tissue[1].

Raloxifene Hcl

Evista (Raloxifene Hydrochloride)

C28H28ClNO4S (509.1427)

D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D020847 - Estrogen Receptor Modulators D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist D050071 - Bone Density Conservation Agents C1892 - Chemopreventive Agent Raloxifene hydrochloride (Keoxifene hydrochloride) is a second generation?selective and orally active estrogen receptor modulator. Raloxifene hydrochloride produces estrogen-agonistic effects on bone and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast tissue[1].

(Methylsulfonyl)octyl glucosinolate

C16H31NO11S3 (509.1059)

Annotation level-3

Cys Cys Glu Arg

(4S)-4-[(2R)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-sulfanylpropanamido]-4-{[(1S)-4-carbamimidamido-1-carboxybutyl]carbamoyl}butanoic acid

C17H31N7O7S2 (509.1726)

Cys Cys Arg Glu

(2S)-2-[(2S)-2-[(2R)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-sulfanylpropanamido]-5-carbamimidamidopentanamido]pentanedioic acid

C17H31N7O7S2 (509.1726)

Cys Asp Ser Trp

(3S)-3-[(2R)-2-amino-3-sulfanylpropanamido]-3-{[(1S)-1-{[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]carbamoyl}-2-hydroxyethyl]carbamoyl}propanoic acid

C21H27N5O8S (509.158)

Cys Asp Trp Ser

(3S)-3-[(2R)-2-amino-3-sulfanylpropanamido]-3-{[(1S)-1-{[(1S)-1-carboxy-2-hydroxyethyl]carbamoyl}-2-(1H-indol-3-yl)ethyl]carbamoyl}propanoic acid

C21H27N5O8S (509.158)

Cys Glu Cys Arg

(2S)-2-[(2R)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-4-carboxybutanamido]-3-sulfanylpropanamido]-5-carbamimidamidopentanoic acid

C17H31N7O7S2 (509.1726)

Cys Glu Met Gln

(4S)-4-[(2R)-2-amino-3-sulfanylpropanamido]-4-{[(1S)-1-{[(1S)-3-carbamoyl-1-carboxypropyl]carbamoyl}-3-(methylsulfanyl)propyl]carbamoyl}butanoic acid